Evaluation of the effects of MCVAC conditioning regimen followed by autologous hematopoietic stem cell transplantation in patients with relapsed and refractory Hodgkin lymphoma: A single-institution retrospective study-Reference-Cited by-同舟云学术

Evaluation of the effects of MCVAC conditioning regimen followed by autologous hematopoietic stem cell transplantation in patients with relapsed and refractory Hodgkin lymphoma: A single-institution retrospective study

Published:2024 Issue: Volume: Page:
ISSN:1346-4280
Container-title:Journal of Clinical and Experimental Hematopathology
language:en
Short-container-title:JCEH

Author:

Naganuma Ken¹,Takahashi Yasuyuki¹,Anan Tomoe¹²,Kizaki Masahiro¹,Momose Shuji³,Higashi Morihiro³,Tabayashi Takayuki¹

Affiliation:

1. Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,

2. Department of Transfusion and Cell Therapy, Saitama Medical Center, Saitama Medical University, Saitama, Japan,

3. Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan

Publisher

Japanese Society for Lymphoreticular Tissue Research

Link

https://www.jstage.jst.go.jp/article/jslrt/advpub/0/advpub_24011/_pdf

Reference22 articles.

1. 1 Ohshima K, Suzumiya J, Kikuchi M. The World Health Organization classification of malignant lymphoma: incidence and clinical prognosis in HTLV-1-endemic area of Fukuoka. Pathol Int. 2002; 52: 1-12.

2. 2 Muto R, Miyoshi H, Sato K et al. Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification. Cancer Med. 2018; 7: 5843-5858.

3. 3 Shah GL, Moskowitz CH. Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood. 2018; 131: 1689-1697.

4. 4 Canellos GP, Abramson JS, Fisher DC, LaCasce AS. Treatment of favorable, limited-stage Hodgkin’s lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol. 2010; 28: 1611-1615.

5. 5 Straus DJ, Długosz-Danecka M, Connors JM et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021; 8: e410-e421.